15950-17-1

Usage

Uses

Used in Pharmaceutical Industry:
(4-Chloro-2-nitro-phenyl)-Methyl-aMine is used as a synthetic intermediate for the production of various pharmaceutical compounds. Its unique molecular structure allows it to be a key component in the synthesis of drugs with specific therapeutic properties.
Used in Chemical Synthesis:
(4-Chloro-2-nitro-phenyl)-Methyl-aMine is used as a reagent in the catalytic hydrogenation process to synthesize 2-(trifluoromethyl)benzimidazole derivatives. These derivatives have potential applications in various fields, including pharmaceuticals, agrochemicals, and materials science, due to their diverse chemical and biological properties.

Upstream product

• 932-96-7 N-methyl(p-chloroaniline) 
• 89-63-4 4-Chloro-2-nitroaniline 
• 77-78-1 dimethyl sulfate 
• 74-89-5 methylamine 
• 89-61-2 2,5-dichloronitrobenzene 
• 23042-32-2 4-chloro-N-methyl-N-nitroaniline 
• 13519-85-2 4-chloro-N-ethyl-N-methylaniline 
• 56288-33-6 4-chloro-N-methyl-N-n-butylaniline 
• 693-05-0 N-(2-cyanoethyl)-N-methylamine 
• 128691-90-7 4-chloro-2-nitrotrifluoroacetanilide 
• 74-88-4 methyl iodide 
• 7664-93-9 sulfuric acid 
• 106-47-8 4-chloro-aniline 
• 15249-31-7 N-phenyl-N-methyl-2-propynamide 

Downstream Products

• 380177-22-0 (N-methyl-5-chloro-1H-benzimidazole-2-yl)methanol 
• 57169-72-9 4-chloro-N-methyl-2,6,N-trinitro-aniline 
• 20927-64-4 N-carbethoxy acetyl N-methyl 2-nitro 4-chloro aniline 
• 61154-66-3 [(4-chloro-2-nitro-phenyl)-methyl-sulfamoyl]-acetic acid 
• 153899-86-6 N-<4-Chlor-2-nitro-phenyl>-N-methyl-ethyl-methyl-cyanessigsaeureamid 
• 154334-37-9 (R)-(-)-N-<4-Chlor-2-nitro-phenyl>-N-methyl-ethyl-methyl-cyanessigsaeureamid 
• 154334-38-0 (S)-(+)-N-<4-Chlor-2-nitro-phenyl>-N-methyl-ethyl-methyl-cyanessigsaeureamid 
• 153899-87-7 N-<4-Chlor-2-nitro-phenyl>-N-methyl-butyl-methyl-cyanessigsaeureamid 
• 154003-63-1 (S)-(+)-N-<4-Chlor-2-nitro-phenyl>-N-methyl-butyl-methyl-cyanessigsaeureamid 
• 59681-66-2 4-chloro-1-N-methylbenzene-1,2-diamine 
• 89659-70-1 (5-Chloro-2-nitro-phenyl)-methyl-carbamic acid ethyl ester 
• 153899-89-9 N-<4-Chlor-2-nitro-phenyl>-N-methyl-ethyl-methyl-malonsaeurediamid 
• 154003-64-2 (R)-(-)-N-<4-Chlor-2-nitro-phenyl>-N-methyl-ethyl-methyl-malonsaeurediamid 
• 154003-65-3 (S)-(+)-N-<4-Chlor-2-nitro-phenyl>-N-methyl-ethyl-methyl-malonsaeurediamid 

Relevant academic research and scientific papers

Selective one-pot N-monomethylation of 2-nitroanilines under PTC conditions

Direct PTC methylation of 2-nitroanilines with dimethyl sulfate gave selectively N-monomethylated products. A variety of N-methyl-2-nitroanilines were prepared in this way.

Cu-Catalyzed C-H Allylation of Benzimidazoles with Allenes

CuH-catalyzed intramolecular cyclization and intermolecular allylation of benzimidazoles with allenes have been described. The reaction proceeded smoothly with the catalytic system of Cu(OAc)2/Xantphos and catalytic amount of (MeO)2MeSiH. This protocol features mild reaction conditions and a good tolerance of substrates bearing electron-withdrawing, electron-donating, or electron-neutral groups. A new catalytic mechanism was proposed for this copper hydride catalytic system.

Oxidative Radical Cyclization of N-methyl-N-arylpropiolamide to Isatins via Cleavage of the Carbon-carbon Triple Bond

A radical cyclization of N-methyl-N-arylpropiolamide to isatins via an oxidative cleavage of a carbon-carbon triple bond has been developed. In the presence of oxone and NaNO2, a variety of N-methyl-N-arylpropiolamides were smoothly transformed into isatins. A nitration reaction proceeded along with the oxidative cyclization; both nitrated and non-nitrated isatins were obtained in a one-pot reaction with moderate to good total yields. This is the first example for the synthesis of isatins via the oxidative radical cleavage of a carbon-carbon triple bond. (Figure presented.).

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

Amino Azaxylylenes Photogenerated from o-Amido Imines: Photoassisted Access to Complex Spiro-Poly-Heterocycles

Upon irradiation, cyclic imines containing o-amido groups are shown to produce reactive intermediates, amino azaxylylenes, which undergo intramolecular cycloadditions to tethered unsaturated pendants to yield complex N,O-heterocycles having an additional spiro-connected nitrogen heterocyclic moiety. Modular assembly of the photoprecursors allows expeditious increase of the complexity of the target poly-heterocyclic scaffolds with a minimal number of experimentally simple reaction steps. The photocyclization and subsequent postphotochemical transformations are accompanied by an increase of Lovering's fsp3 factor, thus producing unprecedented three-dimensional molecular architectures, and offering extended sampling of chemical space. Rings in three dimensions: Cyclic imines containing an o-amido group undergo excited-state intramolecular proton transfer to generate amino azaxylylenes. The amino azaxylylenes undergo intramolecular cycloadditions to tethered unsaturated pendants to yield complex heterocyclic three-dimensional molecular architectures.

Discovery of 2-iminobenzimidazoles as potent hepatitis C virus inhibitors with a novel mechanism of action

In this report we describe 2-iminobenzimidazole (IBI) analogs, identified during the course of a phenotypic high-throughput screening campaign, as novel hepatitis C virus (HCV) inhibitors. A series of IBI derivatives was synthesized and evaluated for their inhibitory activity against infectious HCV. Among the IBIs derivatives studied in this work, we identified promising compounds with high antiviral efficacy, high selectivity index and good microsomal stability. Noteworthy, the IBI series exhibited inhibitory activity on early and late steps of the viral cycle, but not in the HCV replicon system demonstrating a mechanism of action distinct from clinical-stage and approved anti-HCV drugs. Overall, our results suggest that IBIs are predestinated for further exploration as lead compounds for novel HCV interventions.

Discovery of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly

The discovery of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly is described. Synthesis of analogs of the 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione hit established structure-activity relationships. Replacement of the enamine functionality of the hit series with either an imidazole or a pyrazole ring led to compounds that inhibited both capsid assembly and reverse transcriptase. Optimization of the bicyclic benzodiazepine scaffold to include a 3-phenyl substituent led to lead compound 48, a pure capsid assembly inhibitor with improved antiviral activity.

Oxidative coupling of N,N-Dialkylanilines using iodic acid and sodium nitrite

A new reagent system, a combination of iodic acid and sodium nitrite has been investigated for oxidative coupling of N,N-disubstituted anilines. A facile para-selective coupling occurs to give benzidines at room temperature in water as a solvent. A tentative mechanism is proposed with some supporting experiments.

Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators

Compounds of Formula I: wherein A, B, D, L, R1, R2, R3, R4, m, and n are as defined for Formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

CYCLIC GUANIDINES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE

The present invention relates to cyclic guanidines, compositions containing such compounds and methods of treatment. The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus.